CASI
$2.62
Casi Pharmaceuticals
($.13)
(4.73%)
CASI
Earnings Whisper ®
N/A
3rd Quarter September 2023
Consensus:  ($0.56)
Revenue:  $10.40 Mil
Friday
Nov 10
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CASI reports earnings?
Beat
Meet
Miss

Where is CASI's stock price going from here?
Up
Flat
Down
Stock chart of CASI
Analysts
Summary of analysts' recommendations for CASI
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.